These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35172243)

  • 1. The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
    Sousa MJ; Gomes I; Pereira TC; Magalhães J; Basto R; Paulo J; Jacinto P; Bonito N; Sousa G
    Cancer Treat Res Commun; 2022; 31():100531. PubMed ID: 35172243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.
    Tabernero J; Argiles G; Sobrero AF; Borg C; Ohtsu A; Mayer RJ; Vidot L; Moreno Vera SR; Van Cutsem E
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
    Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
    Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
    Karthaus M; Heinemann V; Riera-Knorrenschild J; Kretzschmar A; Welslau M; Kaiser U; Pelz H; Ettrich TJ; Held S; Kehmann L; Hess J; Reisländer T; Weiss L;
    BMC Cancer; 2024 Jul; 24(1):887. PubMed ID: 39044160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis.
    Prejac J; Omrčen T; Radić J; Vrdoljak E; Fröbe A; Pleština S
    Oncology; 2024; 102(3):217-227. PubMed ID: 37699377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
    Stavraka C; Pouptsis A; Synowiec A; Angelis V; Satterthwaite L; Khan S; Chauhan M; Holden C; Young S; Karampera C; Martinou M; Mills-Baldock T; Baxter M; Barry A; Eccles B; Iveson T; Shiu KK; Hill M; Abdel-Raouf S; Graham JS; Thomas A; Ross PJ
    Clin Colorectal Cancer; 2021 Dec; 20(4):342-349. PubMed ID: 34696965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
    Fernández Montes A; Carmona-Bayonas A; Jimenez-Fonseca P; Vázquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; De la Cámara Gómez J; Méndez JCM; Carriles Fernández C; Sanchez Cánovas M; Garcia García T
    Sci Rep; 2021 Jul; 11(1):14321. PubMed ID: 34253805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
    Fernandez Montes A; Vazquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; de la Cámara Gómez J; Méndez Méndez JC; Salgado Fernández M; Candamio Folgar S; Reboredo López M; Carmona Campos M; Gallardo Martín E; Jorge Fernández M; Pellón Augusto ML; París Bouzas L; García Gómez J
    Clin Transl Oncol; 2020 Mar; 22(3):351-359. PubMed ID: 31073972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
    Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
    Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
    ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
    André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
    BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
    Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
    Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.